Signal Genetics (SGNL) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500, Nasdaq set for higher open as investors weigh weaker oil, PPI data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Signal Genetics Highlights Recent Achievements and Reports Second Quarter 2015 Financial Results
August 12, 2015 4:32 PM EDTSigned Master Service Agreement With Leading Pharmaceutical Company Record Volume of MyPRS® Tests Sold to Hospitals Outside of the University of Arkansas for Medical Sciences (UAMS)
CARLSBAD, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ: SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today reported recent achievements and financial results for the second quarter ended June 30, 2015.
Recent Highlights
Announced Master Service... MoreSignal Genetics Highlights Recent Achievements and Reports Second Quarter 2015 Financial Results
August 12, 2015 4:32 PM EDTSigned Master Service Agreement With Leading Pharmaceutical Company Record Volume of MyPRS® Tests Sold to Hospitals Outside of the University of Arkansas for Medical Sciences (UAMS)
CARLSBAD, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ: SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today reported recent achievements and financial results for the second quarter ended June 30, 2015.
Recent Highlights
Announced Master Service... More